Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) – Equities researchers at HC Wainwright boosted their FY2022 earnings per share (EPS) estimates for shares of Bio-Path in a report issued on Tuesday, November 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($1.86) for the year, up from their previous forecast of ($1.87). The consensus estimate for Bio-Path’s current full-year earnings is ($1.76) per share. HC Wainwright also issued estimates for Bio-Path’s Q4 2022 earnings at ($0.48) EPS, Q1 2023 earnings at ($0.46) EPS, Q2 2023 earnings at ($0.46) EPS, Q3 2023 earnings at ($0.41) EPS, Q4 2023 earnings at ($0.37) EPS and FY2023 earnings at ($1.70) EPS.
Separately, StockNews.com initiated coverage on Bio-Path in a research report on Sunday, November 13th. They issued a “sell” rating on the stock.
Bio-Path Stock Performance
Hedge Funds Weigh In On Bio-Path
Several institutional investors and hedge funds have recently modified their holdings of BPTH. Mount Yale Investment Advisors LLC acquired a new stake in shares of Bio-Path during the 3rd quarter worth approximately $81,000. Renaissance Technologies LLC bought a new position in shares of Bio-Path in the second quarter worth about $70,000. Virtu Financial LLC acquired a new stake in shares of Bio-Path in the 3rd quarter valued at approximately $39,000. Finally, Citadel Advisors LLC bought a new stake in shares of Bio-Path during the 3rd quarter valued at approximately $35,000. 5.76% of the stock is currently owned by institutional investors and hedge funds.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
- Get a free copy of the StockNews.com research report on Bio-Path (BPTH)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.